Rakovina Therapeutics Boosts Private Placement to Support Innovations
Rakovina Therapeutics Inc. (TSX-V: RKV) is an innovative biopharmaceutical company dedicated to developing advanced cancer therapies through breakthrough DNA-damage response technologies. In a recent update, the Company announced an increase in its non-brokered private placement offering, raising the total to $2.5 million, a significant uptick from the initial $1.25 million announcement due to strong investor demand.
Details of the Private Placement Offering
The private placement is structured in units which are priced at $0.06 each. Each unit contains one common share along with a warrant that allows the holder to purchase an additional common share at a price of $0.10 per share. The warrants can be exercised over a period of 24 months. Rakovina retains the authority to expedite the warrant exercise period should the 20-day volume-weighted average price of its shares exceed $0.30.
Utilizing Proceeds for Breakthrough Cancer Research
The funds raised through this offering are earmarked for enhancing the Company’s ability to discover and develop innovative cancer treatments. Rakovina has collaborated with cutting-edge Artificial Intelligence (AI) platforms, notably the Deep Docking™ AI platform and the Variational AI Enki™ Platform. This strategic integration of AI is expected to enhance the Company’s efforts in researching and managing its kt-3000 series initiative by fostering partnerships with biotech and pharmaceutical firms.
Regulatory Approvals and Resale Restrictions
It's important to note that this Offering is contingent upon receiving all necessary regulatory approvals, including acceptance from the TSX Venture Exchange. The units will be sold on a non-brokered basis under applicable Canadian securities laws and will adhere to exemptions from prospectus and registration obligations, leading to a four-month plus one-day resale restriction post-issuance.
Rakovina Therapeutics' Commitment to Cancer Treatment
Rakovina Therapeutics Inc. is on a mission to revolutionize cancer treatment through its innovative approach centered around DNA-damage response technologies. The Company has successfully cultivated a pipeline of novel inhibitors that aim to propel one or more drug candidates into human clinical trials, working toward regulatory approval from authorities including Health Canada and the U.S. FDA.
Company Contact Information and Further Inquiries
For further information about Rakovina Therapeutics or the recent private placement, interested parties are invited to reach out to the Company directly. David Hyman, the Chief Financial Officer, can be contacted via email for investor inquiries. Additionally, inquiries related to investment relations and media can be directed to Michelle Seltenrich, who also welcomes communications through the provided email, along with a contact number for immediate assistance.
Frequently Asked Questions
What is the new amount for Rakovina's private placement offering?
The private placement offering has been increased to $2.5 million from the previously announced $1.25 million.
What will the proceeds from the offering be used for?
The proceeds are intended to further the discovery of new cancer treatments and support collaborations with AI platforms.
What are the terms related to the warrants?
Holders can purchase an additional common share at a price of $0.10 per share, with warrants exercisable for 24 months.
Are there any resale restrictions on the securities?
Yes, the securities will be subject to a four-month plus one-day resale restriction from the date of issue.
Who can be contacted for more information?
David Hyman, Chief Financial Officer, can be contacted for investor inquiries, and Michelle Seltenrich for media and investment relations questions.
